Drug Profile
KX2 361
Alternative Names: KX-02; KX-2361Latest Information Update: 10 Apr 2022
Price :
$50
*
At a glance
- Originator Kinex Pharmaceuticals
- Developer Athenex; Guangzhou Xiangxue Pharmaceuticals; Roswell Park Cancer Institute
- Class Antineoplastics; Small molecules
- Mechanism of Action Src-Family kinase inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Brain cancer; Cancer; Glioblastoma; Solid tumours